Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib Meeting Abstract
| Authors: | Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; Abdel-Wahab, O. I.; Durham, B. H. |
| Abstract Title: | Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304039 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.e19081 |
| Notes: | Meeting Abstract: e19081 -- This meeting was also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
457Lacouture -
257Francis -
424Rosenblum -
339Rampal -
573Abdel-Wahab -
203Diamond -
115Durham -
92Rotemberg -
51Yabe -
61Petrova-Drus
Related MSK Work